Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.49 |
| ▸ | THRA | P10827 | 15/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28664590 | 0.89 | THRB (0.52) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600250 | 0.88 | THRA (0.50) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600251 | 0.88 | THRA (0.51) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600247 | 0.87 | THRB (0.54) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600238 | 0.87 | THRA (0.52) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600346 | 0.85 | THRA (0.48) | THRBTHRACYP2C8CYP2C9KMT2A | |
| SCHEMBL24600355 | 0.85 | THRA (0.48) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600240 | 0.84 | THRB (0.52) | THRBTHRACYP2C8CYP2C9NPC1 | |
| SCHEMBL24600350 | 0.82 | THRA (0.54) | THRBTHRACYP2C8CYP2C9MEN1 | |
| SCHEMBL24600362 | 0.82 | THRA (0.54) | THRBTHRACYP2C8CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109863-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC PHARMACEUTICALS, INC (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4273139-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273139-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143574-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 昆药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109863-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | PTH1R, MC2R, TSHR | THRB 16/4885THRA 18/4885CYP2C8 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.